Molecular Studies and Clinical Correlations in Human Prostatic Disease

The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.

Study Overview

• Status: Active, not recruiting
• Conditions: Prostate Cancer

Detailed Description

The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.

• Study Type: Observational
• Enrollment (Actual): 5290

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients meeting the eligibility criteria and receiving or seeking prostate cancer treatment in the Genitourinary Oncology/Urology Services will be approached by a consenting professional at a suitable point in their clinical course prior to biospecimen collection.

Description

Inclusion Criteria:

Men with prostate conditions representing the following disease states:

• No Cancer Diagnosis
• Clinically Localized Disease
• Rising PSA
• Clinical Metastases: Noncastrate
• Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml)
• Signed informed consent

Exclusion Criteria:

-Patients without any prostate related problems.

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Johns Hopkins University; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; University of Chicago; University of Michigan; Genentech, Inc.; University of Wisconsin, Madison; Duke University; University of Southern California; Massachusetts Institute of Technology; Weill Medical College of Cornell University; Oregon Health and Science University; University of Washington; University of California, San Francisco; Fred Hutchinson Cancer Center; Ohio State University; University of Minnesota; Institute of Cancer Research, United Kingdom; Universitätsklinikum Hamburg-Eppendorf; Purdue University; Rockefeller University; General Electric; Rutgers Cancer Institute of New Jersey; Foundation Medicine; Flinders Medical Centre; University of Regensburg; Viatar LLC; Broad Institute; Beckman Coulter GmbH; Exosome Diagnostics, Inc.; The Scripps Research Institute; Epic Sciences; Gen-Probe, Incorporated; Bioview, Inc.; Cold Spring Harbor Laboratory; Janssen Diagnostics, LLC; Brooklyn ImmunoTherapeutics, LLC; Palo Alto Research Center; Biocept, Inc.; Rarecells; Ikonysis; Array Genomics; Nodality; Vitatex Inc.; Serametrix Corporation; Promega Corporation; Creatv Microtech, Inc.; Advanced Cell Diagnostics; ApoCell, Inc.; Clearbridge BioMedics Pte Ltd., Singapore; Cynvenio Biosystems; Fluxion Biosciences; Silicon Biosystems; Innocrin Pharmaceuticals Inc.
• Investigators: Principal Investigator: Susan Slovin, MD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

Helpful Links

• Memorial Sloan Kettering Cancer Center

Study record dates

Study Major Dates

• Study Start: April 1, 1990
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: December 19, 2007
• First Submitted That Met QC Criteria: December 20, 2007
• First Posted (Estimated): December 21, 2007

Study Record Updates

• Last Update Posted (Actual): August 28, 2023
• Last Update Submitted That Met QC Criteria: August 25, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Rising PSA; benign; Clinical Metastases; 90-040
• Additional Relevant MeSH Terms: Urogenital Diseases; Male Urogenital Diseases; Genital Diseases, Male; Genital Diseases; Prostatic Diseases
• Other Study ID Numbers: 90-040